<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58699</article-id><article-id pub-id-type="doi">10.7554/eLife.58699</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The contribution of asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise ship</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-187387"><name><surname>Emery</surname><given-names>Jon C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6644-7604</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187389"><name><surname>Russell</surname><given-names>Timothy W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187385"><name><surname>Liu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187386"><name><surname>Hellewell</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187388"><name><surname>Pearson</surname><given-names>Carl AB</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>CMMID COVID-19 Working Group<contrib-group><contrib contrib-type="author"><name><surname>Atkins</surname><given-names>Katherine E</given-names></name></contrib><contrib contrib-type="author"><name><surname>Klepac</surname><given-names>Petra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Endo</surname><given-names>Akira</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jarvis</surname><given-names>Christopher I</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Nicholas G</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rees</surname><given-names>Eleanor M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meakin</surname><given-names>Sophie R</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rosello</surname><given-names>Alicia</given-names></name></contrib><contrib contrib-type="author"><name><surname>van Zandvoort</surname><given-names>Kevin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Munday</surname><given-names>James D</given-names></name></contrib><contrib contrib-type="author"><name><surname>Edmunds</surname><given-names>W John</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jombart</surname><given-names>Thibaut</given-names></name></contrib><contrib contrib-type="author"><name><surname>Auzenbergs</surname><given-names>Megan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nightingale</surname><given-names>Emily S</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jit</surname><given-names>Mark</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abbott</surname><given-names>Sam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Simons</surname><given-names>David</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bosse</surname><given-names>Nikos I</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leclerc</surname><given-names>Quentin J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Procter</surname><given-names>Simon R</given-names></name></contrib><contrib contrib-type="author"><name><surname>Villabona-Arenas</surname><given-names>C Julian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tully</surname><given-names>Damien C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deol</surname><given-names>Arminder K</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Fiona Yueqian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hué</surname><given-names>Stéphane</given-names></name></contrib><contrib contrib-type="author"><name><surname>Foss</surname><given-names>Anna M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Prem</surname><given-names>Kiesha</given-names></name></contrib><contrib contrib-type="author"><name><surname>Medley</surname><given-names>Graham</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gimma</surname><given-names>Amy</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>Rachel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Clifford</surname><given-names>Samuel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Quaife</surname><given-names>Matthew</given-names></name></contrib><contrib contrib-type="author"><name><surname>Diamond</surname><given-names>Charlie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gibbs</surname><given-names>Hamish P</given-names></name></contrib><contrib contrib-type="author"><name><surname>Quilty</surname><given-names>Billy J</given-names></name></contrib><contrib contrib-type="author"><name><surname>OReilly</surname><given-names>Kathleen</given-names></name></contrib></contrib-group></collab><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-21266"><name><surname>Knight</surname><given-names>Gwenan M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7263-9896</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52045"><name><surname>Eggo</surname><given-names>Rosalind M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-21671"><name><surname>Kucharski</surname><given-names>Adam J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8814-9421</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18737"><name><surname>Funk</surname><given-names>Sebastian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2842-3406</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35621"><name><surname>Flasche</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-20270"><name><surname>Houben</surname><given-names>Rein MGJ</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4132-7467</contrib-id><email>rein.houben@lshtm.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lipsitch</surname><given-names>Marc</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard TH Chan School of Public Health</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo</given-names></name><role>Senior Editor</role><aff><institution>McGill University</institution><country>Canada</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>24</day><month>08</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e58699</elocation-id><history><date date-type="received" iso-8601-date="2020-05-08"><day>08</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-08-23"><day>23</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Emery et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Emery et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58699-v2.pdf"/><abstract><p>A key unknown for SARS-CoV-2 is how asymptomatic infections contribute to transmission. We used a transmission model with asymptomatic and presymptomatic states, calibrated to data on disease onset and test frequency from the Diamond Princess cruise ship outbreak, to quantify the contribution of asymptomatic infections to transmission. The model estimated that 74% (70–78%, 95% posterior interval) of infections proceeded asymptomatically. Despite intense testing, 53% (51–56%) of infections remained undetected, most of them asymptomatic. Asymptomatic individuals were the source for 69% (20–85%) of all infections. The data did not allow identification of the infectiousness of asymptomatic infections, however low ranges (0–25%) required a net reproduction number for individuals progressing through presymptomatic and symptomatic stages of at least 15. Asymptomatic SARS-CoV-2 infections may contribute substantially to transmission. Control measures, and models projecting their potential impact, need to look beyond the symptomatic cases if they are to understand and address ongoing transmission.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>asymptomatic infections</kwd><kwd>subclinical infections</kwd><kwd>transmission</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>Action Number 757699</award-id><principal-award-recipient><name><surname>Emery</surname><given-names>Jon C</given-names></name><name><surname>Houben</surname><given-names>Rein MGJ</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>INV-003174</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>NTD Modelling Consortium OPP1184344</award-id><principal-award-recipient><name><surname>Pearson</surname><given-names>Carl AB</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002992</institution-id><institution>Department for International Development, UK Government</institution></institution-wrap></funding-source><award-id>Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z</award-id><principal-award-recipient><name><surname>Pearson</surname><given-names>Carl AB</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020</institution></institution-wrap></funding-source><award-id>project EpiPose (101003688)</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>HDR UK</institution></institution-wrap></funding-source><award-id>MR/S003975/1</award-id><principal-award-recipient><name><surname>Eggo</surname><given-names>Rosalind M</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><award-id>16/137/109</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yang</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_PC 19065</award-id><principal-award-recipient><name><surname>Eggo</surname><given-names>Rosalind M</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/P014658/1</award-id><principal-award-recipient><name><surname>Knight</surname><given-names>Gwenan M</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>206250/Z/17/Z</award-id><principal-award-recipient><name><surname>Russell</surname><given-names>Timothy W</given-names></name><name><surname>Kucharski</surname><given-names>Adam J</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>208812/Z/17/Z</award-id><principal-award-recipient><name><surname>Flasche</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>210758/Z/18/Z</award-id><principal-award-recipient><name><surname>Hellewell</surname><given-names>Joel</given-names></name><name><surname>Funk</surname><given-names>Sebastian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Nearly 75% of SARS-CoV-2 infections on the Diamond Princess were asymptomatic, half were never detected, and asymptomatic infections may have contributed substantially to transmission.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The ongoing COVID-19 pandemic has spread rapidly across the globe, and the number of individuals infected with SARS-CoV-2 outstrips the number of reported cases (<xref ref-type="bibr" rid="bib39">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Golding et al., 2020</xref>). One key reason for this may be that a substantial proportion of cases proceed asymptomatically, that is, they either do not experience or are not aware of symptoms throughout their infection but may still transmit to others. In this sense, asymptomatic infections differ from presymptomatic infections, which describes the portion of the incubation period before symptoms develop during which onward transmission is possible.</p><p>While pre- and asymptomatic individuals do not directly contribute to morbidity or mortality in an outbreak, they can contribute to ongoing transmission, as has been shown for COVID-19 (<xref ref-type="bibr" rid="bib35">Rothe et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Ganyani et al., 2020</xref>) and other diseases (<xref ref-type="bibr" rid="bib9">Dean et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Slater et al., 2019</xref>; <xref ref-type="bibr" rid="bib12">Esmail et al., 2018</xref>). In particular, purely symptom-based interventions (e.g., self-isolation upon onset of disease) will not interrupt transmission from asymptomatic individuals and hence may be insufficient for outbreak control if a substantial proportion of transmission originates from pre- and asymptomatic infections (<xref ref-type="bibr" rid="bib7">Chen et al., 2020</xref>).</p><p>An estimate of the proportion of infections that progress to symptomatic disease, also known as the case-to-infection ratio, provides an indicator of what proportion of infections will remain undetected by symptom-based case detection (<xref ref-type="bibr" rid="bib36">Salomon and COVID-19 Statistics, Policy modeling, and Epidemiology Collective, 2020</xref>). Evidence so far have suggested that the proportion of SARS-CoV-2 infections that proceed asymptomatically is likely non-trivial (<xref ref-type="bibr" rid="bib24">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib19">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Lavezzo et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Bendavid et al., 2020</xref>), although empirical data are often difficult to interpret due to opportunistic sampling frames (<xref ref-type="bibr" rid="bib30">Nishiura et al., 2020</xref>) combined with low (<xref ref-type="bibr" rid="bib13">Fontanet et al., 2020</xref>) and imbalanced participation from individuals with and without symptoms (<xref ref-type="bibr" rid="bib18">Gudbjartsson et al., 2020</xref>). While it is likely that transmission from asymptomatic individuals can occur, (<xref ref-type="bibr" rid="bib4">Bai et al., 2020</xref>) quantitative estimates are effectively absent. Improved understanding of the relative infectiousness of asymptomatic SARS-CoV-2 infection, and its contribution to overall transmission will greatly improve the ability to estimate the impact of intervention strategies (<xref ref-type="bibr" rid="bib36">Salomon and COVID-19 Statistics, Policy modeling, and Epidemiology Collective, 2020</xref>). What is known is that in the presence of active case-finding, presymptomatic infections and symptomatic cases contribute almost equally to overall transmission, as both modelling and empirical studies have shown (<xref ref-type="bibr" rid="bib25">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib19">He et al., 2020</xref>).</p><p>Documented outbreaks in a closed population with extensive testing of individuals regardless of symptoms provide unique opportunities for improved insights into the dynamics of an infection, as knowledge of the denominator and true proportion infected are crucial, yet often unavailable in other datasets. Here, we use data from the well-documented outbreak on the Diamond Princess cruise ship to capture the mechanics of COVID-19 in a transmission model with explicit asymptomatic and presymptomatic states to infer estimates for the proportion, infectiousness and contribution to transmission of asymptomatic infections. Available data included the date of symptom onset for symptomatic disease for passengers and crew, the number of symptom-agnostic tests administered each day, and the date of positive tests for asymptomatic and presymptomatic individuals (<xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>; <xref ref-type="bibr" rid="bib29">NIID, 2020</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Model calibration</title><p>The model reflected the data well (<xref ref-type="fig" rid="fig1">Figure 1</xref>), including the differently timed peaks for confirmed symptomatic cases for crew (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and passengers (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In addition, the model matched the expected impact of quarantine of passengers on transmission from February 4th as illustrated by the drop in reproductive number (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), followed by a later drop in transmission after February 10th, which was driven by a change in contact pattern in crew. See <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref>–<xref ref-type="fig" rid="fig1s2">2</xref> for full calibration outputs.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A-D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A-C</bold>) and 95% posterior interval only (<bold>D-E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A-B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Marginal posterior parameter values from model calibration.</title><p>Median and equal-tailed 95% marginal posterior parameter values estimated using 100,000 samples from the joint posterior distribution found during MCMC model calibration. See <xref ref-type="table" rid="table2">Table 2</xref> for parameter definitions and descriptions.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58699-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Parameter correlation plot from model calibration.</title><p>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration. See <xref ref-type="table" rid="table2">Table 2</xref> for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Parameter trace plot from model calibration.</title><p>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially. See <xref ref-type="table" rid="table2">Table 2</xref> for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Asymptomatic infections</title><p>We estimated that 74% of infections proceeded asymptomatically (70–78%, 95% Posterior Interval (PI)) (see <xref ref-type="fig" rid="fig2">Figure 2A</xref>). The strong identifiability of this parameter is driven by the relative proportions of individuals testing positive with and without symptoms, combined with the time-delay between symptom-based and symptom-agnostic testing. As a result, our model estimated that in total 1304 (1,198–1,416) individuals were infected, representing 35% (32–38%) of the initial total population on the Diamond Princess. Over half of these infections had not been detected at disembarkation on February 21 st (53%, 51–56%) consisting of infected individuals who had recovered and became test negative before they were tested (37%, 34–40%), were yet to be tested (15%, 13–16%), or had recently been exposed and were not yet detectable at that point (1%, 1–3%). Nearly two-thirds of pre- and asymptomatic infections (67%, 66–68%) and 8% (6–9%) of symptomatic infections went undetected up until disembarkation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Non-linear correlation between relative infectiousness of asymptomatics and their contribution to transmission.</title><p>Correlation between the proportion of transmission from asymptomatics and their relative infectiousness, using 100,000 model runs sampled from the joint posterior distribution. The relationship is non-linear, such that a modest relative infectiousness can still lead to a significant contribution to transmission.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig2-figsupp1-v2.tif"/></fig></fig-group><p>In contrast to the strong identifiability of the proportion of infections that were asymptomatic, the model was unable to identify the relative infectiousness of asymptomatic infections from the data, that is, a uniform prior was effectively returned (see <xref ref-type="fig" rid="fig2">Figure 2B</xref>). This is because the relative infectiousness of asymptomatic infections was degenerate with the overall contact rate, meaning the data were consistent with either relatively frequent contact with less infectious individuals or relatively infrequent contact with more infectious individuals (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Despite this, the estimated proportion of transmission due to asymptomatic infections is 69%, with a wide confidence interval (20–85%) and an interquartile range of 56–76% (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The reason this estimate is not effectively 0–100%, as might be expected by the unidentifiable relative infectiousness, is the combination of the strongly identified, relatively high proportion of infections that are asymptomatic and the non-linear relationship between the relative infectiousness of asymptomatics and their contribution to transmission, which quickly saturates to its maximal value (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The result is that only a modest relative infectiousness is required to produce a non-trivial contribution to transmission. The relative infectiousness of presymptomatics was also unidentifiable, however, in all scenarios the remaining transmission was equally distributed between the presymptomatic (14%, 1–44%) and symptomatic (17%, 11–42%) individuals. <xref ref-type="fig" rid="fig3">Figure 3</xref> shows the instantaneous proportion of transmission from symptomatic (A), presymptomatic (B) and asymptomatic (C) individuals over the course of the epidemic.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Instantaneous proportion of transmission from symptomatic, presymptomatic and asymptomatic individuals.</title><p>Instantaneous proportion of transmission from symptomatic (<bold>A</bold>), presymptomatic (<bold>B</bold>) and asymptomatic (<bold>C</bold>) individuals over the course of the epidemic, following the introduction of a single symptomatic individual on 20th Jan. Red lines = median, shading = 95% posterior interval. Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-fig3-v2.tif"/></fig><p>Because of the non-identifiability of the relative infectiousness of asymptomatic infections we investigated marginal posterior estimates (<xref ref-type="table" rid="table1">Table 1</xref>). We find that low relative infectiousness of asymptomatic infections (0–25% compared to symptomatic individuals) would need to be compensated by a net reproduction number for individuals during their presymptomatic and symptomatic phase of 15.5–29.1.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Model outputs by relative infectiousness of asymptomatic individuals.</title><p>Relative infectiousness expressed as proportion compared to symptomatic individuals. All values are 95% posterior ranges from model scenarios. Net reproduction number represents the typical number of infections generated by a single infected individual during their presymptomatic and symptomatic stages.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top">Range of relative infectiousness of asymptomatic individual</th><th colspan="3" valign="top">Model output</th></tr><tr><th valign="top">Transmission from asymptomatic individuals (%)</th><th valign="top">Net reproduction number for presymptomatic passengers</th><th valign="top">Basic reproduction number</th></tr></thead><tbody><tr><td valign="top">0–1%</td><td valign="bottom">0–3</td><td valign="bottom">22.7–29.1</td><td valign="bottom">6.7–7.6</td></tr><tr><td valign="top">1–25%</td><td valign="bottom">7–58</td><td valign="bottom">15.5–25.5</td><td valign="bottom">7.0–8.8</td></tr><tr><td valign="top">25–50%</td><td valign="bottom">44–75</td><td valign="bottom">11.1–17.6</td><td valign="bottom">8.0–9.6</td></tr><tr><td valign="top">50–75%</td><td valign="bottom">60–82</td><td valign="bottom">8.7–13.6</td><td valign="bottom">8.7–10.2</td></tr><tr><td valign="top">75–99%</td><td valign="bottom">68–86</td><td valign="bottom">7.2–11.4</td><td valign="bottom">9.3–10.8</td></tr><tr><td valign="top">99–100%</td><td valign="bottom">72–87</td><td valign="bottom">6.7–10.2</td><td valign="bottom">9.5–10.9</td></tr></tbody></table><table-wrap-foot><fn><p>Relative infectiousness expressed as proportion compared to symptomatic individuals. All values are 95% posterior ranges from model scenarios. Net reproduction number represents the typical number of infections generated by a single infected individual during their presymptomatic and symptomatic stages.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>Sensitivity analyses</title><p>Without an asymptomatic state the model was unable to reconstruct the dynamics of the outbreak (<xref ref-type="fig" rid="app2fig1">Appendix 2—figures 1</xref>–<xref ref-type="fig" rid="app2fig3">3</xref>, Deviance Information Criterion (DIC) = 974 vs 329 for the primary analysis). Moreover, adjusting the relative value for mixing between crew and passengers did not have a qualitative effect on the results (<xref ref-type="fig" rid="app2fig4">Appendix 2—figures 4</xref>–<xref ref-type="fig" rid="app2fig11">11</xref>).</p><p>Biased symptom-agnostic testing had a greater impact on the results. Those testing negative having a 50% higher probability of being tested compared to the primary analysis led to a corresponding greater proportion of infections that were asymptomatic (84%, 82–87%), total number infected (2,097, 1,914-2,292) and contribution of asymptomatics to transmission (78%, 36–91%) (see <xref ref-type="fig" rid="app2fig12">Appendix 2—figures 12</xref>–<xref ref-type="fig" rid="app2fig15">15</xref>). Conversely, those testing positive having a 50% higher probability of being tested compared to the primary analysis led to a corresponding smaller proportion of infections that were asymptomatic (66%, 61–71%), total number infected (1,051, 965-1,161) and contribution of asymptomatics to transmission (59%, 9–79%) (see <xref ref-type="fig" rid="app2fig16">Appendix 2—figures 16</xref>–<xref ref-type="fig" rid="app2fig19">19</xref>).</p><p>When we assumed a fixed age-specific ratio for the proportion of infections that progress asymptomatically, the model was able to fit the data, although the number of correlated parameters was high. Overall results were similar to the main analysis, with a proportion asymptomatic of 42% (41–44%) and 89% (85–91%) for passengers and crew, respectively. The proportion of all transmission from asymptomatics was 69% (IQR = 59–74%). Relative infectiousness was again unidentifiable. See <xref ref-type="fig" rid="app2fig20">Appendix 2—figures 20</xref>–<xref ref-type="fig" rid="app2fig23">23</xref> for details.</p><p>A longer latent period provided a poorer fit to the data (DIC = 361) (<xref ref-type="fig" rid="app2fig24">Appendix 2—figures 24</xref>–<xref ref-type="fig" rid="app2fig27">27</xref>). Adjusting the duration of the asymptomatic state to half or double the sum of the presymptomatic and symptomatic states made little qualitative difference to the results (<xref ref-type="fig" rid="app2fig28">Appendix 2—figures 28</xref>–<xref ref-type="fig" rid="app2fig35">35</xref>), although the shorter asymptomatic period was a marginally poorer fit to the data (DIC = 338). Finally, recalibrating the model assuming the 35 confirmed pre/asymptomatic cases where a test date was not available were allocated to the last feasible day (13th Feb) made no qualitative difference to our results (see <xref ref-type="fig" rid="app2fig36">Appendix 2—figures 36</xref>–<xref ref-type="fig" rid="app2fig39">39</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>Summary</title><p>We find that in this well-documented outbreak in a closed population, 74% (70–78%) of infections proceeded asymptomatically, equaling a 1:3.8 (1:3.3-1:4.4) case-to-infection ratio. The majority of asymptomatic infections remained undetected, but may have contributed substantially to ongoing transmission. While the relative infectiousness of asymptomatic infections could not be identified, low infectiousness (e.g. 0–25% compared to symptomatic individuals) would have required a very high net reproduction number for individuals during their presymptomatic and symptomatic stages of (15.5–29.1).</p></sec><sec id="s3-2"><title>Interpretation</title><p>Our results are strongly informed by data, which show that when extensive symptom-agnostic testing was ramped up, substantial numbers of pre- or asymptomatic infections were identified. Given the clear suppression of transmission through quarantining, as indicated by the drop in incident symptomatic disease, this finding is most likely explained by a large proportion of undetected asymptomatic individuals.</p><p>The model and data were unable to identify a value for the relative infectiousness, although we showed how different ranges for this key parameter required specific trade-offs, as reflected in the net reproduction number for infected individuals who will develop symptomatic disease. One can argue that a net reproduction number for presymptomatic passengers at the start of the outbreak of over 20 in this population, as required if asymptomatic individuals are effectively unable to transmit (range for relative infectiousness of 0–1%) is unlikely. Such high reproductive numbers are not usually seen, exceeding for example values found for norovirus outbreaks on cruise ships (<xref ref-type="bibr" rid="bib16">Gaythorpe et al., 2018</xref>). While SARS-CoV-2 has been shown to survive on surfaces (<xref ref-type="bibr" rid="bib38">van Doremalen et al., 2020</xref>), this does not seem to be the primary mode of transmission. In combination with growing evidence around viral load in asymptomatic infections and their involvement in transmission chains (<xref ref-type="bibr" rid="bib22">Lavezzo et al., 2020</xref>), as well as anecdotal evidence about transmission from asymptomatic individuals (<xref ref-type="bibr" rid="bib4">Bai et al., 2020</xref>; <xref ref-type="bibr" rid="bib6">Chau et al., 2020</xref>) including in closed populations (<xref ref-type="bibr" rid="bib1">Arons et al., 2020</xref>), it is reasonable to assume that asymptomatic infections play some role in ongoing SARS-CoV transmission. In our model, asymptomatic infections were responsible for more than half of all transmission in 83% of the scenarios compatible with the data.</p><p>It is important to note that our conclusion that asymptomatic infections may have contributed substantially to ongoing transmission is critically dependent on the setting. In this case symptomatic infections were quickly identified and removed from the ship before symptom-agnostic testing began, thereby leaving asymptomatic infections to dominate transmission. Such dominance should therefore not be interpreted as a constant of nature, but instead an important consideration in settings where prompt isolation of symptomatic infections is already in place but with little to no consideration for asymptomatic infections.</p></sec><sec id="s3-3"><title>Comparison to other studies</title><p>Our estimated proportion of asymptomatic infections in this outbreak is higher than previous studies, which relied on diagnosed cases only (<xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>). As we have shown, a substantial number of infections were not detected, which would explain some of the difference. Other empirical studies have found usually lower values, while some found similar ranges. While underestimation in other estimates due to low (<xref ref-type="bibr" rid="bib13">Fontanet et al., 2020</xref>) and imbalanced participation from individuals with and without symptoms (<xref ref-type="bibr" rid="bib18">Gudbjartsson et al., 2020</xref>) will be part of the explanation, there remains scope for unexplained variation from more complete samples (<xref ref-type="bibr" rid="bib22">Lavezzo et al., 2020</xref>). In addition, it is possible that PCR-based testing has a lower sensitivity for asymptomatic individuals, which would further increase the proportion of infections that were asymptomatic (<xref ref-type="bibr" rid="bib6">Chau et al., 2020</xref>).</p><p>A sensitivity analysis showed that our results were robust to age-specific probabilities of progressing to asymptomatic infections, as well as other assumptions made in the model, and driven by trends in the data.</p><p>Our estimated substantial contribution to transmission from asymptomatic infections confirms a hypothesis from Nishiura after analysing symptomatic cases occurring post-disembarkation (<xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>). Our initial reproduction number of 9.3 (7.4–10.6) reflects the high transmission environment expected on cruise ships via increased contacts in a confined space, although lower than the value found in an earlier analysis by <xref ref-type="bibr" rid="bib34">Rocklöv et al., 2020</xref>.</p><p>Our finding of similar contribution to transmission from presymptomatic and symptomatic individuals also matches findings by others (<xref ref-type="bibr" rid="bib15">Ganyani et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib19">He et al., 2020</xref>). In line with this, it is clear that having symptoms, or at least being aware of them, is not required in the transmission of SARS-CoV-2 (<xref ref-type="bibr" rid="bib15">Ganyani et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib19">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Kimball et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Wei et al., 2020</xref>). Although cough is often considered essential for transmission of respiratory infections (<xref ref-type="bibr" rid="bib32">Patterson and Wood, 2019</xref>), work in tuberculosis, influenza and other coronaviruses has shown that while a cough may increase spread, it is not a requirement. Transmission from breathing, talking and sneezing is also possible, as well as transmission from contaminated surfaces (<xref ref-type="bibr" rid="bib38">van Doremalen et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Leung et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Asadi et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Williams et al., 2020</xref>).</p></sec><sec id="s3-4"><title>Limitations</title><p>Additional data, in particular on the distribution of asymptomatic infections across crew and passengers, by age and shared quarantine environments would have benefited the model and potentially enabled us to estimate a range for the relative infectiousness of asymptomatic infections. A serological survey of the population, and the date and testing history of individuals who developed symptoms post-disembarkation, would also have likely informed more precise model estimates. In addition, better evidence on performance of the test used, and the associated likelihood of false-negative or false-positive results would help refine estimates. As more data become available, future model analyses of SARS-CoV-2 dynamics in closed populations should further inform the key questions we have looked to address here.</p><p>Whilst symptom-agnostic testing provided valuable insights into the pre- and asymptomatic states, such testing was not necessarily random, as was assumed in our primary analysis. Indeed, it is known that individuals were generally screened in reverse-age order (<xref ref-type="bibr" rid="bib29">NIID, 2020</xref>). Sensitivity analyses considering biased testing still produced non-trivial results for the proportion of infections that were asymptomatic however.</p><p>Our model also assumed that the infectiousness of all transmissible states was constant over time. If instead symptomatic individuals are most infectious immediately after symptom onset (<xref ref-type="bibr" rid="bib19">He et al., 2020</xref>), an estimate of their contribution to transmission would in principle increase. Given the likely heightened awareness of symptoms on board however, such an increase is likely to be marginal. Indeed, since our assumption of an average one-day, exponentially distributed delay between symptom onset and removal from the ship is likely to be an overestimate, a prompter removal distribution would at least in part offset such an increase.</p><p>A similar simplification was made by assuming that the probability of an individual progressing to either a presymptomatic or asymptomatic infection was independent of who infected whom. It is possible, however, that transmission from a symptomatic infection may be more likely to ultimately result in another symptomatic infection, owing to a higher infecting dose for example.</p></sec><sec id="s3-5"><title>Conclusion</title><p>Asymptomatic SARS-CoV-2 infections may contribute substantially to transmission. This is essential to consider for countries when assessing the potential effectiveness of ongoing control measures to contain COVID-19.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Data</title><p>Data from the Diamond Princess outbreak have been widely reported. (<xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>; <xref ref-type="bibr" rid="bib29">NIID, 2020</xref>) On January 20th, the Diamond Princess cruise ship departed from Yokohama on a tour of Southeast Asia. A passenger that disembarked on January 25th in Hong Kong subsequently tested positive for SARS-CoV-2 on February 1st, reporting the date of symptom onset as January 23rd.</p><p>After arriving back in Yokohama on February 3rd, all passengers and crew were screened for symptoms, and those screening positive were then tested. The ship began quarantine on February 5th with all passengers confined to their cabins and crew undertaking essential activities only. At the start of quarantine there were 3711 individuals on board (2666 passengers and 1045 crew) with a median age of 65 (45–75 interquartile range).</p><p>Testing capacity was limited until February 11th and before then the majority of individuals tested had reported symptoms, referred to here as ‘symptom-based testing’. All individuals with a positive test at any stage were promptly removed from the ship and isolated. After February 11th, testing capacity increased and the testing of individuals irrespective of symptoms, referred to here as ‘symptom-agnostic testing’, was scaled up. In total, 314 symptomatic and 320 pre- or asymptomatic infections were reported before disembarkation was principally completed on February 21st.</p><p>We extracted the following data from <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>; <xref ref-type="bibr" rid="bib29">NIID, 2020</xref> (see <xref ref-type="fig" rid="fig1">Figure 1</xref>). Firstly, the number of symptomatic cases per day (i.e. those testing positive having reported symptoms) by date of symptom onset, separately for passengers and crew. The date of symptom onset was not available for 115 cases, which we accounted for in our model structure by assuming they were distributed over time proportional to those cases with a reported date of symptom onset (see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Secondly, we extracted the number of pre- or asymptomatic infections identified per day (i.e. individuals testing positive having not reported symptoms) by date of test. The test date was not available for 35 pre- or asymptomatic individuals between the February 6-14th, which we assumed were distributed over time proportional to the daily number of tests performed amongst individuals not reporting symptoms. No data were available on how many individuals that tested positive in the absence of symptoms became symptomatic after disembarkation. Finally, we extracted the number of tests performed per day amongst individuals not reporting symptoms (see <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>).</p></sec><sec id="s4-2"><title>Model</title><p>We built a deterministic, compartmental model to capture transmission, disease development and the effect of interventions on board the Diamond Princess. Following exposure, after which an individual is assumed to test negative for SARS-CoV-2 for the duration of the latent phase (see <xref ref-type="table" rid="table2">Table 2</xref>), a proportion of individuals proceed asymptomatically with the remainder becoming presymptomatic. This proportion equates to a universal probability of becoming either presymptomatic or asymptomatic, independent of who infected whom. Individuals in the presymptomatic, asymptomatic or symptomatic state are assumed to test positive and have independent infectiousness, expressed relative to those with symptomatic disease.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Model parameters and priors/values.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Parameter</th><th valign="top">Description</th><th valign="top">Prior/value</th><th valign="top">Source/Notes</th></tr></thead><tbody><tr><td valign="top"><inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:mi>β</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Overall contact rate (1/days)</td><td valign="top">Estimated: Uniform(0,100)</td><td valign="top"/></tr><tr><td valign="top"><inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Relative initial contact rate between crew/crew</td><td valign="top">Fixed: 1</td><td valign="top"/></tr><tr><td valign="top"><inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Relative initial contact rate between passengers/passengers</td><td valign="top">Estimated: Uniform(0,100)</td><td valign="top"/></tr><tr><td valign="top"><inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Relative initial contact rate between passengers/crew</td><td valign="top">Fixed relative to <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top"/></tr><tr><td valign="top"><italic>X</italic></td><td valign="top">Ratio: <inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Fixed: <italic>0.1</italic></td><td valign="top">Assumed. Varied in sensitivity analyses</td></tr><tr><td valign="top"><italic>b</italic><sub>1</sub></td><td valign="top">Percentage reduction in all initial contact rates (%)</td><td valign="top">Estimated: Uniform(0,100)</td><td valign="top"/></tr><tr><td valign="top"><italic>b</italic><sub>2</sub></td><td valign="top">Rate of change of all contact rates (1/days)</td><td valign="top">Fixed: <italic>10</italic></td><td valign="top">Assumed. Transitions completed over approximately one day</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>τ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Time of transition for contacts between passengers/passengers and passengers/crew (days)</td><td valign="top">Estimated: <italic>Uniform(0,32)</italic></td><td valign="top">Assumed to be equal to each other</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>τ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Time of transition for contacts between crew/crew (days)</td><td valign="top">Estimated: Uniform(0,32)</td><td valign="top"/></tr><tr><td valign="top"><inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Relative infectiousness of presymptomatic state</td><td valign="top">Estimated: Uniform(0,1)</td><td valign="top">Relative to symptomatic state</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Relative infectiousness of asymptomatic state</td><td valign="top">Estimated: Uniform(0,1)</td><td valign="top">Relative to symptomatic state</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>χ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Proportion of infections that proceed to asymptomatic state</td><td valign="top">Estimated: Uniform(0,1)</td><td valign="top"/></tr><tr><td valign="top"><inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>v</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Latent period (days)</td><td valign="top">Fixed: <italic>4.3</italic></td><td valign="top">Derived from <xref ref-type="bibr" rid="bib3">Backer et al., 2020</xref></td></tr><tr><td valign="top"><inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Mean duration in asymptomatic state (days)</td><td valign="top">Fixed: 5.0</td><td valign="top">Assumed. Sum of mean durations in presymptomatic and symptomatic states. <break/>Varied in sensitivity analyses.</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>γ</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Mean duration in presymptomatic state (days)</td><td valign="top">Fixed: <italic>2.1</italic> </td><td valign="top">Derived from <xref ref-type="bibr" rid="bib3">Backer et al., 2020</xref></td></tr><tr><td valign="top"><inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>γ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Mean duration in infectious symptomatic state (days).</td><td valign="top">Fixed: <italic>2.9</italic></td><td valign="top">From <xref ref-type="bibr" rid="bib26">Liu et al., 2020b</xref> Applicable only until quarantine starts on 5th Feb</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>μ</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Mean delay between onset of symptomatic disease and symptom-based testing and removal (days).</td><td valign="top">Fixed: <italic>1</italic></td><td valign="top">Assumed. Applicable only after quarantine starts on 5th Feb.</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mi>η</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Mean duration of test positivity following recovery (days)</td><td valign="top">Fixed: <italic>7</italic></td><td valign="top">From <xref ref-type="bibr" rid="bib42">Woelfel et al., 2020</xref></td></tr><tr><td valign="top"><inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ϕ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Proportion of symptomatic cases with a reported onset date</td><td valign="top">Fixed: <italic>0.661</italic> (<italic>199/314</italic>)</td><td valign="top">From <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref></td></tr><tr><td valign="top"><inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Rate of symptom-agnostic testing and removal (1/days)</td><td valign="top">Fixed: <italic>Calculated</italic></td><td valign="top">From <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref> Calculated using the number of tests administered per day amongst individuals not reporting symptoms (see Appendix 1)</td></tr><tr><td valign="top"><inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Total number of passengers on the ship as at start of quarantine on 5th Feb</td><td valign="top">Fixed: 2666</td><td valign="top">From <xref ref-type="bibr" rid="bib29">NIID, 2020</xref></td></tr><tr><td valign="top"><inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula></td><td valign="top">Total number of crew on the ship as at start of quarantine on 5th Feb</td><td valign="top">Fixed: 1045</td><td valign="top">From <xref ref-type="bibr" rid="bib29">NIID, 2020</xref></td></tr></tbody></table></table-wrap><p>Individuals with presymptomatic infection are either detected through symptom-agnostic testing before being removed from the ship, or develop symptomatic disease. Once symptomatic disease starts, individuals can either recover undetected on the ship or, following the start of quarantine on February 5th, be detected through symptom-based testing and removed from the ship with an average delay of one day following symptom onset. We allowed for individuals to test positive after their infectious period for an average of seven days (<xref ref-type="bibr" rid="bib42">Woelfel et al., 2020</xref>). After this, we assume they would test negative.</p><p>Individuals with asymptomatic infections either recover undetected on the ship, or are detected by symptom-agnostic testing before being removed from the ship. See <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref> for a diagram of the model.</p><p>Symptom-agnostic testing was assumed to have been random amongst those not reporting symptoms and no delay was introduced between testing and removal of those that tested positive from the ship. As such, the number of people that tested positive through symptom-agnostic testing before being removed from the ship per day was calculated using the number of tests performed per day (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) and the proportion of individuals that were either presymptomatic, asymptomatic or recovered but continued to test positive for up to seven days, amongst all individuals on the ship not reporting symptoms. All testing was assumed to have 100% sensitivity and specificity.</p><p>Crew and passengers were modelled separately, using stratified data on the number of confirmed symptomatic cases (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref>). We estimated the within-crew and within-passenger contact rates through calibration to the data, but assumed that the between-group contact rate was a fixed factor of 1/10th of the within-passenger rate, and explored the impact of this assumption in sensitivity analyses. We enabled the model to capture potential changes in contact behaviour between individuals by representing contact rates as sigmoid functions over time, reflecting any reductions in contact. The dates and extent of the changes were determined solely through model calibration to the data.</p></sec><sec id="s4-3"><title>Model parameterisation</title><p>We used data from the literature to inform the natural history of COVID-19, in particular for the duration of presymptomatic and symptomatic phases (see <xref ref-type="table" rid="table2">Table 2</xref>).</p></sec><sec id="s4-4"><title>Model calibration</title><p>The model was calibrated in a Bayesian framework. We fitted to the daily incidence of confirmed symptomatic cases with a known onset date, separately for passengers and crew, assuming a Poisson distribution in the likelihood. We simultaneously fitted to the daily number of confirmed pre- and asymptomatic infections for passengers and crew combined by using the number of tests administered per day and the prevalence of presymptomatic, asymptomatic and post-infection test-positive individuals, assuming a binomial distribution in the likelihood. We used uniform priors for the parameters to be estimated (see <xref ref-type="table" rid="table2">Table 2</xref>) and sampled the posterior of the model parameters using sequential Markov Chain Monte-Carlo (MCMC). A burn in phase during which the proposal distributions were adapted in both scale and shape to provide optimal sampling efficiency was discarded, leaving chains with 1.5 million iterations. The resultant MCMC chains were visually inspected for convergence.</p></sec><sec id="s4-5"><title>Model outputs</title><p>Model outputs were calculated by randomly sampling 100,000 parameter values from the posterior distribution. Model trajectories were generated and compared to the data in <xref ref-type="fig" rid="fig1">Figure 1A–C</xref> to inspect model fit. The basic reproduction number was also calculated over time using the next-generation matrix (<xref ref-type="bibr" rid="bib10">Diekmann et al., 2010</xref>), as a measure of ongoing transmission. We estimated the proportion of infections that become asymptomatic and the relative infectiousness of asymptomatic infections using their respective marginal posterior parameter values. Finally, the contribution of asymptomatic infections to overall transmission, as well as the net reproduction number for presymptomatic passengers at the beginning of the outbreak (i.e. the typical number of infections generated by a single presymptomatic individual) were estimated, both overall and by specific ranges of relative infectiousness. We report the median and 95% equal-tailed posterior intervals throughout.</p></sec><sec id="s4-6"><title>Sensitivity analyses</title><p>We recalibrated the model for a number of alternative scenarios to assess model sensitivity. Firstly, we assessed the impact of removing the asymptomatic phase (i.e. 100% of infections progressed to symptomatic disease). Secondly, we explored the impact of assuming different values for the relative mixing between crew and passengers as well as shorter and longer durations of asymptomatic infection. Thirdly, we considered the impact of biased symptom-agnostic testing. Specifically, we first assumed that those that would test positive were 50% more likely to be tested, before then assuming that those that would test negative were 50% more likely to be tested, both compared to purely random testing as per the primary analysis. We also explored the impact of assuming a different proportion of asymptomatic infections for crew and passengers based on their distinct median ages (36 years for crew, 69 years for passengers), using a fixed ratio for the two proportions taken from the results of a model fitted to epidemic data in six countries by <xref ref-type="bibr" rid="bib8">Davies et al., 2020</xref>. In addition, we explored a longer latent period given the relatively high age in our population (<xref ref-type="bibr" rid="bib20">Jiang et al., 2020</xref>). Finally, we recalibrated the model assuming the 35 confirmed pre/asymptomatic cases where a test date was not available were allocated to the last feasible day (13th Feb) instead of proportionate to the overall number of tests over the period February 6-14th(see Appendix 2 for further details).</p><p>All analyses were conducted using R version 3.5.0 (<xref ref-type="bibr" rid="bib33">R Development Core Team, 2014</xref>). Bayesian calibration was performed in LibBi (<xref ref-type="bibr" rid="bib28">Murray, 2013</xref>) using RBi (<xref ref-type="bibr" rid="bib14">Funk, 2019</xref>) as an interface. Replication data and analyses scripts are available on GitHub at <ext-link ext-link-type="uri" xlink:href="https://github.com/thimotei/covid19_asymptomatic_trans">https://github.com/thimotei/covid19_asymptomatic_trans</ext-link> (<xref ref-type="bibr" rid="bib11">Emery et al., 2020</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/covid19_asymptomatic_trans">https://github.com/elifesciences-publications/covid19_asymptomatic_trans</ext-link>).</p></sec><sec id="s4-7"><title>Role of funding source</title><p>The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank Dr Taichi Kidani for help in translating primary data sources.</p><p>The following funding sources are acknowledged as providing funding for the named authors. This research was partly funded by the Bill and Melinda Gates Foundation (INV-003174: YL; NTD Modelling Consortium OPP1184344: CABP). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP). ERC Starting Grant (#757699: JCE, RMGJH). This project has received funding from the European Union’s Horizon 2020 research and innovation programme - project EpiPose (101003688: YL). HDR UK (MR/S003975/1: RME). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (16/137/109: YL). UK MRC (MC_PC 19065: RME; MR/P014658/1: GMK). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 208812/Z/17/Z: SFlasche; 210758/Z/18/Z: JH, SFunk).</p><p>The following funding sources are acknowledged as providing funding for the CMMID COVID-19 working group. Alan Turing Institute (AE). BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill and Melinda Gates Foundation (INV-003174: KP, MJ; NTD Modelling Consortium OPP1184344: GM; OPP1180644: SRP; OPP1183986: ESN; OPP1191821: KO’R, MA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: KvZ). Elrha R2HC/UK DFID/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757699: MQ). This project has received funding from the European Union’s Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, WJE). This research was partly funded by the Global Challenges Research Fund (GCRF) project ‘RECAP’ managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, TJ). Nakajima Foundation (AE). NIHR (16/137/109: BJQ, CD, FYS, MJ; Health Protection Research Unit for Modelling Methodology HPRU-2012–10096: NGD, TJ; PR-OD-1017–20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: EMR, QJL). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (208812/Z/17/Z: SC; 210758/Z/18/Z: JDM, NIB, SA, SRM). No funding (AKD, AMF, DCT, SH).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Software, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Software, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Software, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Software, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-58699-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data analysed during this study are included in the manuscript and supporting files. Model code and data are available through github at <ext-link ext-link-type="uri" xlink:href="https://github.com/thimotei/covid19_asymptomatic_trans">https://github.com/thimotei/covid19_asymptomatic_trans</ext-link> (copy archived at<ext-link ext-link-type="uri" xlink:href="https://github.com/elifesciences-publications/covid19_asymptomatic_trans">https://github.com/elifesciences-publications/covid19_asymptomatic_trans</ext-link>).</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arons</surname> <given-names>MM</given-names></name><name><surname>Hatfield</surname> <given-names>KM</given-names></name><name><surname>Reddy</surname> <given-names>SC</given-names></name><name><surname>Kimball</surname> <given-names>A</given-names></name><name><surname>James</surname> <given-names>A</given-names></name><name><surname>Jacobs</surname> <given-names>JR</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Spicer</surname> <given-names>K</given-names></name><name><surname>Bardossy</surname> <given-names>AC</given-names></name><name><surname>Oakley</surname> <given-names>LP</given-names></name><name><surname>Tanwar</surname> <given-names>S</given-names></name><name><surname>Dyal</surname> <given-names>JW</given-names></name><name><surname>Harney</surname> <given-names>J</given-names></name><name><surname>Chisty</surname> <given-names>Z</given-names></name><name><surname>Bell</surname> <given-names>JM</given-names></name><name><surname>Methner</surname> <given-names>M</given-names></name><name><surname>Paul</surname> <given-names>P</given-names></name><name><surname>Carlson</surname> <given-names>CM</given-names></name><name><surname>McLaughlin</surname> <given-names>HP</given-names></name><name><surname>Thornburg</surname> <given-names>N</given-names></name><name><surname>Tong</surname> <given-names>S</given-names></name><name><surname>Tamin</surname> <given-names>A</given-names></name><name><surname>Tao</surname> <given-names>Y</given-names></name><name><surname>Uehara</surname> <given-names>A</given-names></name><name><surname>Harcourt</surname> <given-names>J</given-names></name><name><surname>Clark</surname> <given-names>S</given-names></name><name><surname>Brostrom-Smith</surname> <given-names>C</given-names></name><name><surname>Page</surname> <given-names>LC</given-names></name><name><surname>Kay</surname> <given-names>M</given-names></name><name><surname>Lewis</surname> <given-names>J</given-names></name><name><surname>Montgomery</surname> <given-names>P</given-names></name><name><surname>Stone</surname> <given-names>ND</given-names></name><name><surname>Clark</surname> <given-names>TA</given-names></name><name><surname>Honein</surname> <given-names>MA</given-names></name><name><surname>Duchin</surname> <given-names>JS</given-names></name><name><surname>Jernigan</surname> <given-names>JA</given-names></name><collab>Public Health–Seattle and King County and CDC COVID-19 Investigation Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>2081</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2008457</pub-id><pub-id pub-id-type="pmid">32329971</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asadi</surname> <given-names>S</given-names></name><name><surname>Wexler</surname> <given-names>AS</given-names></name><name><surname>Cappa</surname> <given-names>CD</given-names></name><name><surname>Barreda</surname> <given-names>S</given-names></name><name><surname>Bouvier</surname> <given-names>NM</given-names></name><name><surname>Ristenpart</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aerosol emission and superemission during human speech increase with voice loudness</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>2348</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-38808-z</pub-id><pub-id pub-id-type="pmid">30787335</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backer</surname> <given-names>JA</given-names></name><name><surname>Klinkenberg</surname> <given-names>D</given-names></name><name><surname>Wallinga</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020</article-title><source>Eurosurveillance</source><volume>25</volume><elocation-id>2000062</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.5.2000062</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname> <given-names>Y</given-names></name><name><surname>Yao</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>T</given-names></name><name><surname>Tian</surname> <given-names>F</given-names></name><name><surname>Jin</surname> <given-names>D-Y</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Presumed asymptomatic carrier transmission of COVID-19</article-title><source>Jama</source><volume>323</volume><fpage>1406</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2565</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Bendavid</surname> <given-names>E</given-names></name><name><surname>Mulaney</surname> <given-names>B</given-names></name><name><surname>Sood</surname> <given-names>N</given-names></name><name><surname>Shah</surname> <given-names>S</given-names></name><name><surname>Ling</surname> <given-names>E</given-names></name><name><surname>Bromley-Dulfano</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 antibody seroprevalence in santa clara county, California</article-title><source>Epidemiology</source><ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.04.14.20062463">http://medrxiv.org/lookup/doi/10.1101/2020.04.14.20062463</ext-link><date-in-citation iso-8601-date="2020-04-18">April 18, 2020</date-in-citation></element-citation></ref><ref id="bib6"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Chau</surname> <given-names>NVV</given-names></name><name><surname>Lam</surname> <given-names>VT</given-names></name><name><surname>Dung</surname> <given-names>NT</given-names></name><name><surname>Yen</surname> <given-names>LM</given-names></name><name><surname>Minh</surname> <given-names>NNQ</given-names></name><name><surname>Hung</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The natural history and transmission potential of asymptomatic SARS-CoV-2 infection</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.27.20082347</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>A</given-names></name><name><surname>Yi</surname> <given-names>B</given-names></name><name><surname>Keqin</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The epidemiological characteristics of infection in close contacts of COVID-19 in Ningbo City</article-title><source>Chin J Epidemiol</source><volume>41</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.3760/cma.j.cn112338-20200304-00251</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>NG</given-names></name><name><surname>Klepac</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Prem</surname> <given-names>K</given-names></name><name><surname>Jit</surname> <given-names>M</given-names></name><collab>CMMID COVID-19 working group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Age-dependent effects in the transmission and control of COVID-19 epidemics</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.24.20043018</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname> <given-names>NE</given-names></name><name><surname>Halloran</surname> <given-names>ME</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Longini</surname> <given-names>IM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transmissibility and pathogenicity of ebola virus: a systematic review and Meta-analysis of household secondary attack rate and asymptomatic infection</article-title><source>Clinical Infectious Diseases</source><volume>62</volume><fpage>1277</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw114</pub-id><pub-id pub-id-type="pmid">26932131</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diekmann</surname> <given-names>O</given-names></name><name><surname>Heesterbeek</surname> <given-names>JAP</given-names></name><name><surname>Roberts</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The construction of next-generation matrices for compartmental epidemic models</article-title><source>Journal of the Royal Society Interface</source><volume>7</volume><fpage>873</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1098/rsif.2009.0386</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Emery</surname> <given-names>JC</given-names></name><name><surname>Russell</surname> <given-names>TW</given-names></name><name><surname>Funk</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>The contribution of asymptomatic SARS-CoV-2 infections to transmission - a model-based analysis of the Diamond Princess outbreak</data-title><source>GitHub</source><version designator="116b196">116b196</version><ext-link ext-link-type="uri" xlink:href="https://github.com/thimotei/covid19_asymptomatic_trans">https://github.com/thimotei/covid19_asymptomatic_trans</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmail</surname> <given-names>H</given-names></name><name><surname>Dodd</surname> <given-names>PJ</given-names></name><name><surname>Houben</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tuberculosis transmission during the subclinical period: could unrelated cough play a part?</article-title><source>The Lancet Respiratory Medicine</source><volume>6</volume><fpage>244</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(18)30105-X</pub-id><pub-id pub-id-type="pmid">29595504</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Fontanet</surname> <given-names>A</given-names></name><name><surname>Tondeur</surname> <given-names>L</given-names></name><name><surname>Madec</surname> <given-names>Y</given-names></name><name><surname>Grant</surname> <given-names>R</given-names></name><name><surname>Besombes</surname> <given-names>C</given-names></name><name><surname>Jolly</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cluster of COVID-19 in northern France: a retrospective closed cohort study</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.18.20071134</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Funk</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Sbfnk/RBi</source><version designator="43e77da">43e77da</version><ext-link ext-link-type="uri" xlink:href="https://github.com/sbfnk/RBi">https://github.com/sbfnk/RBi</ext-link></element-citation></ref><ref id="bib15"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ganyani</surname> <given-names>T</given-names></name><name><surname>Kremer</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Torneri</surname> <given-names>A</given-names></name><name><surname>Faes</surname> <given-names>C</given-names></name><name><surname>Wallinga</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimating the generation interval for COVID-19 based on symptom onset data</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.03.05.20031815</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaythorpe</surname> <given-names>KAM</given-names></name><name><surname>Trotter</surname> <given-names>CL</given-names></name><name><surname>Lopman</surname> <given-names>B</given-names></name><name><surname>Steele</surname> <given-names>M</given-names></name><name><surname>Conlan</surname> <given-names>AJK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Norovirus transmission dynamics: a modelling review</article-title><source>Epidemiology and Infection</source><volume>146</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1017/S0950268817002692</pub-id><pub-id pub-id-type="pmid">29268812</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Golding</surname> <given-names>N</given-names></name><name><surname>Russell</surname> <given-names>TW</given-names></name><name><surname>Abbott</surname> <given-names>S</given-names></name><name><surname>Hellewell</surname> <given-names>J</given-names></name><name><surname>Pearson</surname> <given-names>CAB</given-names></name><name><surname>van Zandvoort</surname> <given-names>K</given-names></name><name><surname>Jarvis</surname> <given-names>CI</given-names></name><name><surname>Gibbs</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Eggo</surname> <given-names>RM</given-names></name><name><surname>Edmunds</surname> <given-names>JW</given-names></name><name><surname>Kucharski</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reconstructing the global dynamics of under-ascertained COVID-19 cases and infections</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.07.20148460</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudbjartsson</surname> <given-names>DF</given-names></name><name><surname>Helgason</surname> <given-names>A</given-names></name><name><surname>Jonsson</surname> <given-names>H</given-names></name><name><surname>Magnusson</surname> <given-names>OT</given-names></name><name><surname>Melsted</surname> <given-names>P</given-names></name><name><surname>Norddahl</surname> <given-names>GL</given-names></name><name><surname>Saemundsdottir</surname> <given-names>J</given-names></name><name><surname>Sigurdsson</surname> <given-names>A</given-names></name><name><surname>Sulem</surname> <given-names>P</given-names></name><name><surname>Agustsdottir</surname> <given-names>AB</given-names></name><name><surname>Eiriksdottir</surname> <given-names>B</given-names></name><name><surname>Fridriksdottir</surname> <given-names>R</given-names></name><name><surname>Gardarsdottir</surname> <given-names>EE</given-names></name><name><surname>Georgsson</surname> <given-names>G</given-names></name><name><surname>Gretarsdottir</surname> <given-names>OS</given-names></name><name><surname>Gudmundsson</surname> <given-names>KR</given-names></name><name><surname>Gunnarsdottir</surname> <given-names>TR</given-names></name><name><surname>Gylfason</surname> <given-names>A</given-names></name><name><surname>Holm</surname> <given-names>H</given-names></name><name><surname>Jensson</surname> <given-names>BO</given-names></name><name><surname>Jonasdottir</surname> <given-names>A</given-names></name><name><surname>Jonsson</surname> <given-names>F</given-names></name><name><surname>Josefsdottir</surname> <given-names>KS</given-names></name><name><surname>Kristjansson</surname> <given-names>T</given-names></name><name><surname>Magnusdottir</surname> <given-names>DN</given-names></name><name><surname>le Roux</surname> <given-names>L</given-names></name><name><surname>Sigmundsdottir</surname> <given-names>G</given-names></name><name><surname>Sveinbjornsson</surname> <given-names>G</given-names></name><name><surname>Sveinsdottir</surname> <given-names>KE</given-names></name><name><surname>Sveinsdottir</surname> <given-names>M</given-names></name><name><surname>Thorarensen</surname> <given-names>EA</given-names></name><name><surname>Thorbjornsson</surname> <given-names>B</given-names></name><name><surname>Löve</surname> <given-names>A</given-names></name><name><surname>Masson</surname> <given-names>G</given-names></name><name><surname>Jonsdottir</surname> <given-names>I</given-names></name><name><surname>Möller</surname> <given-names>AD</given-names></name><name><surname>Gudnason</surname> <given-names>T</given-names></name><name><surname>Kristinsson</surname> <given-names>KG</given-names></name><name><surname>Thorsteinsdottir</surname> <given-names>U</given-names></name><name><surname>Stefansson</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Spread of SARS-CoV-2 in the icelandic population</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>2302</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2006100</pub-id><pub-id pub-id-type="pmid">32289214</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Lau</surname> <given-names>EHY</given-names></name><name><surname>Wu</surname> <given-names>P</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Hao</surname> <given-names>X</given-names></name><name><surname>Lau</surname> <given-names>YC</given-names></name><name><surname>Wong</surname> <given-names>JY</given-names></name><name><surname>Guan</surname> <given-names>Y</given-names></name><name><surname>Tan</surname> <given-names>X</given-names></name><name><surname>Mo</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Liao</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Hu</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Zhong</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Cowling</surname> <given-names>BJ</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Leung</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0869-5</pub-id><pub-id pub-id-type="pmid">32296168</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>AB</given-names></name><name><surname>Lieu</surname> <given-names>R</given-names></name><name><surname>Quenby</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Significantly longer Covid-19 incubation times for the elderly from a case study of 136 patients throughout China</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.04.14.20065896</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname> <given-names>A</given-names></name><name><surname>Hatfield</surname> <given-names>KM</given-names></name><name><surname>Arons</surname> <given-names>M</given-names></name><name><surname>James</surname> <given-names>A</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Spicer</surname> <given-names>K</given-names></name><name><surname>Bardossy</surname> <given-names>AC</given-names></name><name><surname>Oakley</surname> <given-names>LP</given-names></name><name><surname>Tanwar</surname> <given-names>S</given-names></name><name><surname>Chisty</surname> <given-names>Z</given-names></name><name><surname>Bell</surname> <given-names>JM</given-names></name><name><surname>Methner</surname> <given-names>M</given-names></name><name><surname>Harney</surname> <given-names>J</given-names></name><name><surname>Jacobs</surname> <given-names>JR</given-names></name><name><surname>Carlson</surname> <given-names>CM</given-names></name><name><surname>McLaughlin</surname> <given-names>HP</given-names></name><name><surname>Stone</surname> <given-names>N</given-names></name><name><surname>Clark</surname> <given-names>S</given-names></name><name><surname>Brostrom-Smith</surname> <given-names>C</given-names></name><name><surname>Page</surname> <given-names>LC</given-names></name><name><surname>Kay</surname> <given-names>M</given-names></name><name><surname>Lewis</surname> <given-names>J</given-names></name><name><surname>Russell</surname> <given-names>D</given-names></name><name><surname>Hiatt</surname> <given-names>B</given-names></name><name><surname>Gant</surname> <given-names>J</given-names></name><name><surname>Duchin</surname> <given-names>JS</given-names></name><name><surname>Clark</surname> <given-names>TA</given-names></name><name><surname>Honein</surname> <given-names>MA</given-names></name><name><surname>Reddy</surname> <given-names>SC</given-names></name><name><surname>Jernigan</surname> <given-names>JA</given-names></name><collab>Public Health – Seattle &amp; King County</collab><collab>CDC COVID-19 Investigation Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a Long-Term care skilled nursing facility - King county, Washington, march 2020</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>69</volume><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6913e1</pub-id><pub-id pub-id-type="pmid">32240128</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Lavezzo</surname> <given-names>E</given-names></name><name><surname>Franchin</surname> <given-names>E</given-names></name><name><surname>Ciavarella</surname> <given-names>C</given-names></name><name><surname>Cuomo-Dannenburg</surname> <given-names>G</given-names></name><name><surname>Barzon</surname> <given-names>L</given-names></name><name><surname>Del Vecchio</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Suppression of COVID-19 outbreak in the municipality of vo, Italy</article-title><source>Epidemiology</source><ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.04.17.20053157v1">https://www.medrxiv.org/content/10.1101/2020.04.17.20053157v1</ext-link><date-in-citation iso-8601-date="2020-04-19">April 19, 2020</date-in-citation></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname> <given-names>NHL</given-names></name><name><surname>Chu</surname> <given-names>DKW</given-names></name><name><surname>Shiu</surname> <given-names>EYC</given-names></name><name><surname>Chan</surname> <given-names>K-H</given-names></name><name><surname>McDevitt</surname> <given-names>JJ</given-names></name><name><surname>Hau</surname> <given-names>BJP</given-names></name><name><surname>Yen</surname> <given-names>H-L</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Ip</surname> <given-names>DKM</given-names></name><name><surname>Peiris</surname> <given-names>JSM</given-names></name><name><surname>Seto</surname> <given-names>W-H</given-names></name><name><surname>Leung</surname> <given-names>GM</given-names></name><name><surname>Milton</surname> <given-names>DK</given-names></name><name><surname>Cowling</surname> <given-names>BJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Respiratory virus shedding in exhaled breath and efficacy of face masks</article-title><source>Nature Medicine</source><volume>26</volume><fpage>676</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0843-2</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Pei</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Song</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>W</given-names></name><name><surname>Shaman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)</article-title><source>Science</source><volume>368</volume><fpage>489</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1126/science.abb3221</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Funk</surname> <given-names>S</given-names></name><name><surname>Flasche</surname> <given-names>S</given-names></name><collab>Centre for Mathematical Modelling of Infectious Diseases nCoV Working Group</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019</article-title><source>Wellcome Open Research</source><volume>5</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15788.1</pub-id><pub-id pub-id-type="pmid">32685697</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Kang</surname> <given-names>M</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Zhong</surname> <given-names>H</given-names></name><name><surname>Xiao</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Transmission dynamics of 2019 novel coronavirus (2019-nCoV)</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.01.25.919787</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizumoto</surname> <given-names>K</given-names></name><name><surname>Kagaya</surname> <given-names>K</given-names></name><name><surname>Zarebski</surname> <given-names>A</given-names></name><name><surname>Chowell</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020</article-title><source>Eurosurveillance</source><volume>25</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.10.2000180</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bayesian State-Space modelling on High-Performance hardware using LibBi</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1306.3277">https://arxiv.org/abs/1306.3277</ext-link></element-citation></ref><ref id="bib29"><element-citation publication-type="web"><person-group person-group-type="author"><collab>NIID</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Field briefing: diamond princess COVID-19 cases</article-title><ext-link ext-link-type="uri" xlink:href="https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html">https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html</ext-link><date-in-citation iso-8601-date="2020-03-12">March 12, 2020</date-in-citation></element-citation></ref><ref id="bib30"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Nishiura</surname> <given-names>H</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Miyama</surname> <given-names>T</given-names></name><name><surname>Suzuki</surname> <given-names>A</given-names></name><name><surname>Jung</surname> <given-names>S</given-names></name><name><surname>Hayashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) [Internet]</article-title><source>Epidemiology</source><ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.02.03.20020248">http://medrxiv.org/lookup/doi/10.1101/2020.02.03.20020248</ext-link><date-in-citation iso-8601-date="2020-03-17">March 17, 2020</date-in-citation></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiura</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Backcalculating the incidence of infection with COVID-19 on the diamond princess</article-title><source>Journal of Clinical Medicine</source><volume>9</volume><elocation-id>657</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9030657</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname> <given-names>B</given-names></name><name><surname>Wood</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Is cough really necessary for TB transmission?</article-title><source>Tuberculosis</source><volume>117</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2019.05.003</pub-id><pub-id pub-id-type="pmid">31378265</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><year iso-8601-date="2014">2014</year><data-title>R: A Language and Environment for Statistical Computing</data-title><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocklöv</surname> <given-names>J</given-names></name><name><surname>Sjödin</surname> <given-names>H</given-names></name><name><surname>Wilder-Smith</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 outbreak on the diamond princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures</article-title><source>Journal of Travel Medicine</source><volume>27</volume><elocation-id>taaa030</elocation-id><pub-id pub-id-type="doi">10.1093/jtm/taaa030</pub-id><pub-id pub-id-type="pmid">32109273</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothe</surname> <given-names>C</given-names></name><name><surname>Schunk</surname> <given-names>M</given-names></name><name><surname>Sothmann</surname> <given-names>P</given-names></name><name><surname>Bretzel</surname> <given-names>G</given-names></name><name><surname>Froeschl</surname> <given-names>G</given-names></name><name><surname>Wallrauch</surname> <given-names>C</given-names></name><name><surname>Zimmer</surname> <given-names>T</given-names></name><name><surname>Thiel</surname> <given-names>V</given-names></name><name><surname>Janke</surname> <given-names>C</given-names></name><name><surname>Guggemos</surname> <given-names>W</given-names></name><name><surname>Seilmaier</surname> <given-names>M</given-names></name><name><surname>Drosten</surname> <given-names>C</given-names></name><name><surname>Vollmar</surname> <given-names>P</given-names></name><name><surname>Zwirglmaier</surname> <given-names>K</given-names></name><name><surname>Zange</surname> <given-names>S</given-names></name><name><surname>Wölfel</surname> <given-names>R</given-names></name><name><surname>Hoelscher</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>970</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001468</pub-id><pub-id pub-id-type="pmid">32003551</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Salomon</surname> <given-names>JA</given-names></name><collab>COVID-19 Statistics, Policy modeling, and Epidemiology Collective</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Defining high-value information for COVID-19 decision-making [Internet]</article-title><source>Health Policy</source><ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.04.06.20052506">http://medrxiv.org/lookup/doi/10.1101/2020.04.06.20052506</ext-link><date-in-citation iso-8601-date="2020-04-20">April 20, 2020</date-in-citation></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname> <given-names>HC</given-names></name><name><surname>Ross</surname> <given-names>A</given-names></name><name><surname>Felger</surname> <given-names>I</given-names></name><name><surname>Hofmann</surname> <given-names>NE</given-names></name><name><surname>Robinson</surname> <given-names>L</given-names></name><name><surname>Cook</surname> <given-names>J</given-names></name><name><surname>Gonçalves</surname> <given-names>BP</given-names></name><name><surname>Björkman</surname> <given-names>A</given-names></name><name><surname>Ouedraogo</surname> <given-names>AL</given-names></name><name><surname>Morris</surname> <given-names>U</given-names></name><name><surname>Msellem</surname> <given-names>M</given-names></name><name><surname>Koepfli</surname> <given-names>C</given-names></name><name><surname>Mueller</surname> <given-names>I</given-names></name><name><surname>Tadesse</surname> <given-names>F</given-names></name><name><surname>Gadisa</surname> <given-names>E</given-names></name><name><surname>Das</surname> <given-names>S</given-names></name><name><surname>Domingo</surname> <given-names>G</given-names></name><name><surname>Kapulu</surname> <given-names>M</given-names></name><name><surname>Midega</surname> <given-names>J</given-names></name><name><surname>Owusu-Agyei</surname> <given-names>S</given-names></name><name><surname>Nabet</surname> <given-names>C</given-names></name><name><surname>Piarroux</surname> <given-names>R</given-names></name><name><surname>Doumbo</surname> <given-names>O</given-names></name><name><surname>Doumbo</surname> <given-names>SN</given-names></name><name><surname>Koram</surname> <given-names>K</given-names></name><name><surname>Lucchi</surname> <given-names>N</given-names></name><name><surname>Udhayakumar</surname> <given-names>V</given-names></name><name><surname>Mosha</surname> <given-names>J</given-names></name><name><surname>Tiono</surname> <given-names>A</given-names></name><name><surname>Chandramohan</surname> <given-names>D</given-names></name><name><surname>Gosling</surname> <given-names>R</given-names></name><name><surname>Mwingira</surname> <given-names>F</given-names></name><name><surname>Sauerwein</surname> <given-names>R</given-names></name><name><surname>Paul</surname> <given-names>R</given-names></name><name><surname>Riley</surname> <given-names>EM</given-names></name><name><surname>White</surname> <given-names>NJ</given-names></name><name><surname>Nosten</surname> <given-names>F</given-names></name><name><surname>Imwong</surname> <given-names>M</given-names></name><name><surname>Bousema</surname> <given-names>T</given-names></name><name><surname>Drakeley</surname> <given-names>C</given-names></name><name><surname>Okell</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The temporal dynamics and infectiousness of subpatent <italic>Plasmodium falciparum</italic> infections in relation to parasite density</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1433</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09441-1</pub-id><pub-id pub-id-type="pmid">30926893</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname> <given-names>N</given-names></name><name><surname>Bushmaker</surname> <given-names>T</given-names></name><name><surname>Morris</surname> <given-names>DH</given-names></name><name><surname>Holbrook</surname> <given-names>MG</given-names></name><name><surname>Gamble</surname> <given-names>A</given-names></name><name><surname>Williamson</surname> <given-names>BN</given-names></name><name><surname>Tamin</surname> <given-names>A</given-names></name><name><surname>Harcourt</surname> <given-names>JL</given-names></name><name><surname>Thornburg</surname> <given-names>NJ</given-names></name><name><surname>Gerber</surname> <given-names>SI</given-names></name><name><surname>Lloyd-Smith</surname> <given-names>JO</given-names></name><name><surname>de Wit</surname> <given-names>E</given-names></name><name><surname>Munster</surname> <given-names>VJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>1564</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><pub-id pub-id-type="pmid">32182409</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name><name><surname>Hao</surname> <given-names>X</given-names></name><name><surname>Guo</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolving epidemiology and impact of Non-pharmaceutical interventions on the outbreak of coronavirus disease 2019 in Wuhan, China [Internet]</article-title><source>Epidemiology</source><ext-link ext-link-type="uri" xlink:href="http://medrxiv.org/lookup/doi/10.1101/2020.03.03.20030593">http://medrxiv.org/lookup/doi/10.1101/2020.03.03.20030593</ext-link><date-in-citation iso-8601-date="2020-04-10">April 10, 2020</date-in-citation></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>WE</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Chiew</surname> <given-names>CJ</given-names></name><name><surname>Yong</surname> <given-names>SE</given-names></name><name><surname>Toh</surname> <given-names>MP</given-names></name><name><surname>Lee</surname> <given-names>VJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020</article-title><source>MMWR. Morbidity and Mortality Weekly Report</source><volume>69</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6914e1</pub-id><pub-id pub-id-type="pmid">32271722</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>CM</given-names></name><name><surname>Abdulwhhab</surname> <given-names>M</given-names></name><name><surname>Birring</surname> <given-names>SS</given-names></name><name><surname>De Kock</surname> <given-names>E</given-names></name><name><surname>Garton</surname> <given-names>NJ</given-names></name><name><surname>Townsend</surname> <given-names>E</given-names></name><name><surname>Pareek</surname> <given-names>M</given-names></name><name><surname>Al-Taie</surname> <given-names>A</given-names></name><name><surname>Pan</surname> <given-names>J</given-names></name><name><surname>Ganatra</surname> <given-names>R</given-names></name><name><surname>Stoltz</surname> <given-names>AC</given-names></name><name><surname>Haldar</surname> <given-names>P</given-names></name><name><surname>Barer</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies</article-title><source>The Lancet Infectious Diseases</source><volume>20</volume><fpage>607</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(19)30707-8</pub-id><pub-id pub-id-type="pmid">32085847</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woelfel</surname> <given-names>R</given-names></name><name><surname>Corman</surname> <given-names>VM</given-names></name><name><surname>Guggemos</surname> <given-names>W</given-names></name><name><surname>Seilmaier</surname> <given-names>M</given-names></name><name><surname>Zange</surname> <given-names>S</given-names></name><name><surname>Mueller</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster</article-title><source>Infectious Diseases</source><volume>1</volume><elocation-id>502</elocation-id><pub-id pub-id-type="doi">10.1101/2020.03.05.20030502</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><sec id="s8" sec-type="appendix"><title>Extended methods</title><sec id="s8-1"><title>Data</title><p>Data for confirmed symptomatic cases were extracted from <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>. <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> shows n = 199 confirmed symptomatic cases by date of symptom onset for passengers and crew separately. Symptom onset dates were unavailable for a further n = 115 confirmed symptomatic cases. These were accounted for in the model structure (see <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>) by assuming they were distributed over time proportional to those cases with a reported date of symptom onset. The data itself were not augmented.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Confirmed symptomatic cases (n = 199) by date of symptom onset for passengers and crew separately, extracted from <xref ref-type="bibr" rid="bib31">Nishiura, 2020</xref>.</title><p>A further n = 115 confirmed symptomatic cases without symptom onset dates are not included in the table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Date of symptom onset</th><th colspan="3">Confirmed symptomatic cases</th></tr><tr><th>Passengers</th><th>Crew</th><th>Total</th></tr></thead><tbody><tr><td>20-Jan</td><td>2</td><td>0</td><td>2</td></tr><tr><td>21-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>22-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>23-Jan</td><td>1</td><td>0</td><td>1</td></tr><tr><td>24-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>25-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>26-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>27-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>28-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>29-Jan</td><td>1</td><td>0</td><td>1</td></tr><tr><td>30-Jan</td><td>1</td><td>0</td><td>1</td></tr><tr><td>31-Jan</td><td>0</td><td>0</td><td>0</td></tr><tr><td>01-Feb</td><td>4</td><td>0</td><td>4</td></tr><tr><td>02-Feb</td><td>4</td><td>0</td><td>4</td></tr><tr><td>03-Feb</td><td>4</td><td>0</td><td>4</td></tr><tr><td>04-Feb</td><td>6</td><td>0</td><td>6</td></tr><tr><td>05-Feb</td><td>12</td><td>0</td><td>12</td></tr><tr><td>06-Feb</td><td>15</td><td>2</td><td>17</td></tr><tr><td>07-Feb</td><td>29</td><td>2</td><td>31</td></tr><tr><td>08-Feb</td><td>17</td><td>2</td><td>19</td></tr><tr><td>09-Feb</td><td>19</td><td>5</td><td>24</td></tr><tr><td>10-Feb</td><td>7</td><td>3</td><td>10</td></tr><tr><td>11-Feb</td><td>11</td><td>8</td><td>19</td></tr><tr><td>12-Feb</td><td>5</td><td>7</td><td>12</td></tr><tr><td>13-Feb</td><td>9</td><td>8</td><td>17</td></tr><tr><td>14-Feb</td><td>2</td><td>5</td><td>7</td></tr><tr><td>15-Feb</td><td>1</td><td>3</td><td>4</td></tr><tr><td>16-Feb</td><td>0</td><td>3</td><td>3</td></tr><tr><td>17-Feb</td><td>0</td><td>1</td><td>1</td></tr><tr><td>18-Feb</td><td>0</td><td>0</td><td>0</td></tr><tr><td>19-Feb</td><td>0</td><td>0</td><td>0</td></tr><tr><td>20-Feb</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Total</td><td>150</td><td>49</td><td>199</td></tr></tbody></table></table-wrap><p>Data for confirmed pre/asymptomatic cases and symptom-agnostic testing were extracted from <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>. <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref> shows n = 2749 symptom-agnostic tests and n = 320 confirmed pre/asymptomatic cases by date of test for passengers and crew combined, since stratification by passenger/crew was unavailable. The number of symptom-agnostic tests was inferred from the total number of tests each day, minus the number of positive results in individuals reporting symptoms in <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>. Test dates were not available for n = 35 confirmed pre/asymptomatic cases between 5th-14th Feb. These were distributed proportional to the total number of tests (symptom-based and symptom-agnostic) on those days. An alternative scenario where all n = 35 confirmed pre/asymptomatic cases are allocated to the last possible day (13th Feb) is explored in sensitivity analyses.</p><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Confirmed pre/asymptomatic cases (n = 320) and symptom-agnostic tests (n = 2749) by date of test for passengers and crew combined, extracted from <xref ref-type="bibr" rid="bib27">Mizumoto et al., 2020</xref>.</title><p><sup>+</sup>Test dates were not available for n = 35 confirmed pre/asymptomatic cases between 5th-14th Feb. These were distributed proportional to the total number of tests (symptom-based and symptom-agnostic) on those days.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Date of test</th><th>Number of symptom agnostic tests</th><th>Number of confirmed pre/asymptomatic cases</th></tr></thead><tbody><tr><td>20-Jan</td><td>0</td><td>0</td></tr><tr><td>21-Jan</td><td>0</td><td>0</td></tr><tr><td>22-Jan</td><td>0</td><td>0</td></tr><tr><td>23-Jan</td><td>0</td><td>0</td></tr><tr><td>24-Jan</td><td>0</td><td>0</td></tr><tr><td>25-Jan</td><td>0</td><td>0</td></tr><tr><td>26-Jan</td><td>0</td><td>0</td></tr><tr><td>27-Jan</td><td>0</td><td>0</td></tr><tr><td>28-Jan</td><td>0</td><td>0</td></tr><tr><td>29-Jan</td><td>0</td><td>0</td></tr><tr><td>30-Jan</td><td>0</td><td>0</td></tr><tr><td>31-Jan</td><td>0</td><td>0</td></tr><tr><td>01-Feb</td><td>0</td><td>0</td></tr><tr><td>02-Feb</td><td>0</td><td>0</td></tr><tr><td>03-Feb</td><td>0</td><td>0</td></tr><tr><td>04-Feb</td><td>0</td><td>0</td></tr><tr><td>05-Feb<sup>+</sup></td><td>23</td><td>2</td></tr><tr><td>06-Feb<sup>+</sup></td><td>64</td><td>3</td></tr><tr><td>07-Feb<sup>+</sup></td><td>138</td><td>8</td></tr><tr><td>08-Feb<sup>+</sup></td><td>3</td><td>0</td></tr><tr><td>09-Feb<sup>+</sup></td><td>54</td><td>3</td></tr><tr><td>10-Feb<sup>+</sup></td><td>43</td><td>5</td></tr><tr><td>11-Feb<sup>+</sup></td><td>0</td><td>0</td></tr><tr><td>12-Feb<sup>+</sup></td><td>17</td><td>3</td></tr><tr><td>13-Feb<sup>+</sup></td><td>188</td><td>11</td></tr><tr><td>14-Feb<sup>+</sup></td><td>0</td><td>0</td></tr><tr><td>15-Feb</td><td>188</td><td>38</td></tr><tr><td>16-Feb</td><td>257</td><td>38</td></tr><tr><td>17-Feb</td><td>475</td><td>70</td></tr><tr><td>18-Feb</td><td>658</td><td>65</td></tr><tr><td>19-Feb</td><td>596</td><td>68</td></tr><tr><td>20-Feb</td><td>45</td><td>6</td></tr><tr><td>Total</td><td>2749</td><td>320</td></tr></tbody></table></table-wrap></sec><sec id="s8-2"><title>Model</title><p>The model described in the main article is shown in detail in <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>, where passengers (<inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) and crew (<inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) are modelled separately and the annotated parameters are described in <xref ref-type="table" rid="table2">Table 2</xref> in the main article.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Model diagram for the outbreak onboard the Diamond Princess cruise ship described in the main paper.</title><p>The annotated transition parameters are defined in <xref ref-type="table" rid="table2">Table 2</xref> in the main article and detailed further, below. The model is stratified by i = passengers or crew. The asymptomatic, presymptomatic and symptomatic states are all assumed to be infectious and individuals would test positive during symptom-based or symptom-agnostic testing. Individuals that recover are also assumed to test positive for an average of 1 week after they are no longer infectious.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app1-fig1-v2.tif"/></fig><p>The force of infection is given by<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mo movablelimits="false">∑</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:munder><mml:mo>⁡</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mrow><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>a</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:mrow><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>u</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula>where the time dependent contact parameters are described by sigmoid functions<disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mover><mml:mi>β</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo>−</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>−</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>And <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mi>p</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> (i.e. contact between passengers/passengers and passengers/crew is reduced at the same time, which can differ from contact between crew/crew).</p><p>The transition from exposed to presymptomatic or asymptomatic is modelled as an erlang distribution using two compartments (i.e. a shape parameter <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>), each with a mean duration of <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mi>v</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>The rate of symptom agnostic testing and removal of individuals not reporting symptoms is given by the total number of symptom agnostic tests administered per day divided by the total number of individuals not presenting symptoms being tested on that day<disp-formula id="equ3"><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>Where <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> is taken from the data in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref> and variables without indices represent the totals among passengers and crew (e.g. <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula>)</p><p>To reflect heightened symptom awareness following quarantine, the transition rate from symptomatic infection to recovered on the ship is constant before quarantine and zero afterwards, whilst the rate of removal of individuals reporting symptoms is zero before quarantine and a constant afterwards<disp-formula id="equ4"><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:mrow><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:mrow><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mrow><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mrow><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:mrow><mml:mi>s</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mrow><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/></mml:mtd><mml:mtd><mml:mrow><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi>t</mml:mi><mml:mo>≥</mml:mo><mml:mrow><mml:mrow><mml:mn>5</mml:mn><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:mrow><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">b</mml:mi></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>All other model transitions are exponentially distributed.</p><p>The model is initialised with a single symptomatic passenger with a known onset date on 20th Jan, with all other individuals susceptible<disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>c</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msup><mml:mi>N</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>c</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s8-3"><title>Model calibration</title><p>The model was calibrated in a Bayesian framework to fit to the two sets of empirical observations from the ship (<xref ref-type="table" rid="app1table1">Appendix 1—tables 1</xref>–<xref ref-type="table" rid="app1table2">2</xref>). We used a Poisson likelihood for the incident symptomatic cases with a known onset date for crew and passengers separately. We used a Binomial likelihood for the number of confirmed pre- and asymptomatic infections for passengers and crew combined, using the number of tests administered per day and the prevalence of presymptomatic, asymptomatic and post-infection test-positive individuals. The complete likelihood is given by<disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mrow><mml:mo movablelimits="false">∏</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mo>⁡</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>Z</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>c</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>c</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mrow><mml:mo movablelimits="false">∏</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mo>⁡</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>Z</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mrow><mml:mo movablelimits="false">∏</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>K</mml:mi></mml:munderover><mml:mo>⁡</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mspace width="thickmathspace"/><mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></disp-formula>where <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">Z</mml:mi><mml:mi mathvariant="normal">k</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the observed incidence of symptomatic cases with a known date of onset on day <italic>k</italic> for passengers <italic>p</italic> or crew <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mi>z</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> is the model predicted incidence, <inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the observed prevalence of presymptomatic, asymptomatic and post-infection test-positive individuals (passengers and crew combined) amongst <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> symptom-agnostic tests, and <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is the model predicted prevalence<disp-formula id="equ7"><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>y</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo>+</mml:mo><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mi>C</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>We used uniform priors for the parameters to be estimated (see <xref ref-type="table" rid="table2">Table 2</xref> in the main article).</p></sec><sec id="s8-4"><title>Model outputs</title><p>The basic reproduction number as a function of time <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> was calculated by first constructing the next generation matrix (NGM) at each time point using the relevant Jacobian matrices (<xref ref-type="bibr" rid="bib10">Diekmann et al., 2010</xref>). The basic reproduction number is then given by the absolute value of the dominant eigenvalue of the NGM.</p><p>The net reproduction number for a presymptomatic infection (i.e. the typical number of secondary infections caused by a single presymptomatic individual throughout both their presymptomatic and symptomatic periods) at the beginning of the outbreak is given by the respective entry in the NGM evaluated at <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>The instantaneous proportion of transmission from either symptomatic, presymptomatic or asymptomatic individuals was calculated by dividing the number of infections generated by the respective infected state in the previous timestep by the total number of new infections in the previous timestep. The overall proportion of transmission from asymptomatic individuals was given by the cumulative number of infections caused by asymptomatics divided by the cumulative number of total infections, evaluated at the end of the outbreak.</p></sec></sec></boxed-text></app><app id="appendix-2"><title>Appendix 2</title><boxed-text><sec id="s9" sec-type="appendix"><title>Sensitivity analyses results</title><sec id="s9-1"><title>1. Presymptomatic infection only</title><p>Assumes the proportion of infections that are asymptomatic and their relative infectiousness are zero (<inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>χ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>). The latent period <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> is estimated with a uniform prior between 1 and 21 days.</p><fig id="app2fig1" position="float"><label>Appendix 2—figure 1.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig1-v2.tif"/></fig><fig id="app2fig2" position="float"><label>Appendix 2—figure 2.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig2-v2.tif"/></fig><fig id="app2fig3" position="float"><label>Appendix 2—figure 3.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig3-v2.tif"/></fig></sec><sec id="s9-2"><title>2. Relative passenger-crew contact rate: X = 0.02</title><p>Assumes the contact rate between passengers and crew is 1/50th of contacts between passengers and passengers <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><fig id="app2fig4" position="float"><label>Appendix 2—figure 4.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig4-v2.tif"/></fig><fig id="app2fig5" position="float"><label>Appendix 2—figure 5.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig5-v2.tif"/></fig><fig id="app2fig6" position="float"><label>Appendix 2—figure 6.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig6-v2.tif"/></fig><fig id="app2fig7" position="float"><label>Appendix 2—figure 7.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig7-v2.tif"/></fig></sec><sec id="s9-3"><title>3. Relative passenger-crew contact rate: X = 0.5</title><p>Assumes the contact rates between passengers and crew is half that of between passengers and passengers <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mi>c</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><fig id="app2fig8" position="float"><label>Appendix 2—figure 8.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig8-v2.tif"/></fig><fig id="app2fig9" position="float"><label>Appendix 2—figure 9.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig9-v2.tif"/></fig><fig id="app2fig10" position="float"><label>Appendix 2—figure 10.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig10-v2.tif"/></fig><fig id="app2fig11" position="float"><label>Appendix 2—figure 11.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig11-v2.tif"/></fig></sec><sec id="s9-4"><title>4. Biased symptom-agnostic testing: test-negative individuals more likely to be tested</title><p>Assumes individuals that would test negative during symptom-agnostic testing are 50% more likely to be tested compared to the primary analysis, where testing is random.</p><fig id="app2fig12" position="float"><label>Appendix 2—figure 12.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig12-v2.tif"/></fig><fig id="app2fig13" position="float"><label>Appendix 2—figure 13.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig13-v2.tif"/></fig><fig id="app2fig14" position="float"><label>Appendix 2—figure 14.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig14-v2.tif"/></fig><fig id="app2fig15" position="float"><label>Appendix 2—figure 15.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig15-v2.tif"/></fig></sec><sec id="s9-5"><title>5. Biased symptom-agnostic testing: test-positive individuals more likely to be tested</title><p>Assumes individuals that would test positive during symptom-agnostic testing are 50% more likely to be tested compared to the primary analysis, where testing is random.</p><fig id="app2fig16" position="float"><label>Appendix 2—figure 16.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig16-v2.tif"/></fig><fig id="app2fig17" position="float"><label>Appendix 2—figure 17.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig17-v2.tif"/></fig><fig id="app2fig18" position="float"><label>Appendix 2—figure 18.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig18-v2.tif"/></fig><fig id="app2fig19" position="float"><label>Appendix 2—figure 19.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig19-v2.tif"/></fig></sec><sec id="s9-6"><title>6. Age dependent proportion asymptomatic</title><p>Assumes separate asymptomatic proportions for crew <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> and passengers <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> to reflect their different age demographics (median ages of 36 and 69 respectively), compared to a single asymptomatic proportion in the primary analysis. The ratio <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mtext> </mml:mtext><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mstyle></mml:math></inline-formula> was fixed at 0.48 using the results for asymptomatic proportion by age from a model fitted to epidemic data in six countries by <xref ref-type="bibr" rid="bib8">Davies et al., 2020</xref>.</p><fig id="app2fig20" position="float"><label>Appendix 2—figure 20.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig20-v2.tif"/></fig><fig id="app2fig21" position="float"><label>Appendix 2—figure 21.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. The left hand peak is for passengers, whilst the right hand peak is for crew. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig21-v2.tif"/></fig><fig id="app2fig22" position="float"><label>Appendix 2—figure 22.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig22-v2.tif"/></fig><fig id="app2fig23" position="float"><label>Appendix 2—figure 23.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig23-v2.tif"/></fig></sec><sec id="s9-7"><title>7. Duration of latent period: 8.8 days</title><p>Assumes the average duration for the latent period is <inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>v</mml:mi><mml:mo>=</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days (<xref ref-type="bibr" rid="bib20">Jiang et al., 2020</xref>), compared to 4.3 in the primary analysis.</p><fig id="app2fig24" position="float"><label>Appendix 2—figure 24.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig24-v2.tif"/></fig><fig id="app2fig25" position="float"><label>Appendix 2—figure 25.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig25-v2.tif"/></fig><fig id="app2fig26" position="float"><label>Appendix 2—figure 26.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig26-v2.tif"/></fig><fig id="app2fig27" position="float"><label>Appendix 2—figure 27.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig27-v2.tif"/></fig></sec><sec id="s9-8"><title>8. Duration of asymptomatic infection: 2.5 days</title><p>Assumes the average duration of asymptomatic infection is <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>2.5</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days, compared to 5 days in the primary analysis.</p><fig id="app2fig28" position="float"><label>Appendix 2—figure 28.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig28-v2.tif"/></fig><fig id="app2fig29" position="float"><label>Appendix 2—figure 29.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig29-v2.tif"/></fig><fig id="app2fig30" position="float"><label>Appendix 2—figure 30.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig30-v2.tif"/></fig><fig id="app2fig31" position="float"><label>Appendix 2—figure 31.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig31-v2.tif"/></fig></sec><sec id="s9-9"><title>9. Duration of asymptomatic infection: 10 days</title><p>Assumes the average duration of asymptomatic infection is <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> days, compared to 5 days in the primary analysis.</p><fig id="app2fig32" position="float"><label>Appendix 2—figure 32.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig32-v2.tif"/></fig><fig id="app2fig33" position="float"><label>Appendix 2—figure 33.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig33-v2.tif"/></fig><fig id="app2fig34" position="float"><label>Appendix 2—figure 34.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig34-v2.tif"/></fig><fig id="app2fig35" position="float"><label>Appendix 2—figure 35.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig35-v2.tif"/></fig></sec><sec id="s9-10"><title>10. Alternative distribution of n = 35 confirmed pre/asymptomatic cases</title><p>Assumes that n = 35 confirmed pre/asymptomatic cases without a test are apportioned to the last possible day (13th Feb), compared to proportional to the total number of tests administered over 6th-13th Feb in the primary analysis.</p><fig id="app2fig36" position="float"><label>Appendix 2—figure 36.</label><caption><title>Data from the Diamond Princess and model calibration.</title><p>Figure shows data from the Diamond Princess (points (<bold>A–D</bold>) and bars (<bold>F</bold>)) and results from model calibration. Red lines = median, shading = 95% posterior plus observational interval (<bold>A–C</bold>) and 95% posterior interval only (<bold>D–E</bold>). Two vertical lines show the date of the first confirmed diagnosis (left) and the start of quarantine measures (right). (<bold>A–B</bold>) show confirmed symptomatic cases among crew (<bold>A</bold>) and passengers (<bold>B</bold>) with a reported date of onset; (<bold>C</bold>) shows confirmed pre- or asymptomatic individuals by test date; (<bold>D</bold>) shows the prevalence of pre/asymptomatic individuals by test date. Points and error bars show point estimates and 95% confidence intervals; (<bold>E</bold>) shows the basic reproduction number over time for the ship as a whole, reflecting the drop in contact rates (<bold>F</bold>) shows the number of tests administered irrespective of symptoms, by test date.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig36-v2.tif"/></fig><fig id="app2fig37" position="float"><label>Appendix 2—figure 37.</label><caption><title>Proportion of infections that are asymptomatic and their contribution to transmission.</title><p>(<bold>A</bold>) Prior (blue) and posterior (red) probability distribution for the proportion progressing to asymptomatic infections. (<bold>B</bold>) Prior (blue) and posterior (red) probability distribution for the relative infectiousness of asymptomatic infections. (<bold>C</bold>) Number of pre- and asymptomatic infections and symptomatic cases detected (dark red) and not detected (light red) during the outbreak. Error bars indicate 95% posterior intervals. (<bold>D</bold>) Posterior probability distribution for proportion of transmission that is from asymptomatic individuals. Dashed and dotted lines show median and interquartile range respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig37-v2.tif"/></fig><fig id="app2fig38" position="float"><label>Appendix 2—figure 38.</label><caption><title>Parameter correlation plot containing parameter values from 10,000 samples of the joint posterior distribution found during MCMC model calibration.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig38-v2.tif"/></fig><fig id="app2fig39" position="float"><label>Appendix 2—figure 39.</label><caption><title>Parameter trace plot showing all 1.5 million samples from the MCMC model calibration sequentially.</title><p>See <xref ref-type="table" rid="table2">Table 2</xref> in the main article for parameter definitions and descriptions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58699-app2-fig39-v2.tif"/></fig></sec></sec></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58699.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lipsitch</surname><given-names>Marc</given-names></name><role>Reviewing Editor</role><aff><institution>Harvard TH Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lipsitch</surname><given-names>Marc</given-names></name><role>Reviewer</role><aff><institution>Harvard TH Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is a very detailed model-based workup of the Diamond Princess outbreak that is thoughtfully done, extracts tremendous insight from a messy dataset, and provides a good example of how rich such outbreak workups can be in elucidating features of transmission.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The contribution of asymptomatic SARS-CoV-2 to transmission – a modelling analysis of the Diamond Princess outbreak&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, including Marc Lipsitch as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below mainly address clarity and presentation (one sensitivity analysis requested in point 7 and one optionally in point 6).</p><p>We thank the authors for their patience during the review process, during which expert reviewers have been understandably rather overstretched.</p><p>Summary:</p><p>Excellent paper providing careful analysis of valuable data on asymptomatic transmission. [From reviewer 3]: This article is a very important analysis that provides a result of immediate interest to the field as well as to policymakers dealing with the pandemic. The analysis is conducted well and the manuscript describes the approach well, as well as providing several sensitivity analyses to demonstrate the robustness of the results. I have a few suggestions for pieces of the analysis to clarify and potential sensitivity analyses to add, but I believe this work should be published soon as it is important information to contribute to the discussion in the field.</p><p>Essential revisions:</p><p>1) I wish some more intuition (or any) could be provided for why infectiousness of asymptomatics is not identified but proportion asymptomatic so strongly is and contribution to transmission somewhat is.</p><p>2) I wonder how sensitive the results are to the assumptions about the flat contagiousness over the natural history. If symptomatics were most infectious during their early days of symptoms (as viral load data suggest) then their removal would do less to reduce their infectiousness and they would contribute more to transmission (I think). Some sensitivity analysis to this would be helpful.</p><p>3) How well supported by data is the 1 day mean (and exponential distribution, which is probably wrong) of time to removal post-test+? Does changing this to an immediate end to infectiousness (presumably people are very careful around known positives) change things?</p><p>4) The conclusions are critically conditional on the setting. This needs to be emphasized in a whole paragraph of the Discussion, including how they might change in a setting of less intense testing and removal. For example if symptomatic test+ people are removed very fast (on average) this will increase the proportion of transmission by asymptomatics, at least in a period where only symptomatics are tested. So it is important to avoid the situation where this high proportion of contribution to transmission becomes interpreted as a constant of nature rather than a property of transmission on the DP.</p><p>5) I would like to see more explanation of why it is possible to id the % asymptomatic, and their contribution to transmission, but not a quantity that is related to the ratio of these: their relative infectiousness.</p><p>6) It appears that asymptomatic infections occur independently (i.e., an individual infected by someone who is asymptomatic is no more or less likely to be asymptomatic themselves). Is this correct? If so, it is worth mentioning the assumption and possible consequences of it in the Materials and methods and Discussion. This could be an additional sensitivity analysis as well.</p><p>7) It would be helpful to explain the assumptions about the testing regime in the main text. Sensitivity analyses should also consider if the testing is not truly random sampling of non-symptomatic individuals. E.g., what if individuals with infection are more likely to get tested (low-level symptoms they do not report)? Or what if individuals with infection are less likely to get tested (health-seeking behavior)? Since it relates directly to the number of asymptomatic infections in the model, it might have a larger effect than some of the other sensitivity tests.</p><p>8) If possible, it would be good to see the percentage of infections that are by pre and asymptomatic individuals by date, to see how it changes with the progression of the epidemic and the progression to symptoms within individuals.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58699.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) I wish some more intuition (or any) could be provided for why infectiousness of asymptomatics is not identified but proportion asymptomatic so strongly is and contribution to transmission somewhat is.</p></disp-quote><p>We have added additional details to the Results section under ‘Asymptomatic infections’ to help provide more intuition for our results.</p><p>In particular, we have noted that with respect to the proportion asymptomatic:</p><p>“The strong identifiability of this parameter is driven by the relative proportions of individuals testing positive with and without symptoms, combined with the time delay between symptom-based and symptom-agnostic testing”.</p><p>Thereafter, with respect to the unidentifiability of relative infectiousness of asymptomatics, we note that:</p><p>“This is because the relative infectiousness of asymptomatic infections was degenerate with the overall contact rate, meaning the data was consistent with either relatively frequent contact with less infectious individuals or relatively infrequent contact with more infectious individuals (see Figure 1—figure supplement 1).”</p><p>Finally, with respect to the contribution of asymptomatics to overall transmission, we detail that:</p><p>“The reason this estimate is not effectively 0-100%, as might be expected by the unidentifiable relative infectiousness, is the combination of the strongly identified, relatively high proportion of infections that are asymptomatic and the non-linear relationship between the relative infectiousness of asymptomatics and their contribution to transmission, which quickly saturates to its maximal value (see Figure 2—figure supplement 1). The result is that only a modest relative infectiousness is required to produce a non-trivial contribution to transmission.”</p><disp-quote content-type="editor-comment"><p>2) I wonder how sensitive the results are to the assumptions about the flat contagiousness over the natural history. If symptomatics were most infectious during their early days of symptoms (as viral load data suggest) then their removal would do less to reduce their infectiousness and they would contribute more to transmission (I think). Some sensitivity analysis to this would be helpful.</p></disp-quote><p>We thank the reviewer for this interesting question. We have added the following paragraph to the Discussion, under ‘Limitations’, that considers both this point as well as point 3 below:</p><p>“Our model also assumed that the infectiousness of all transmissible states was constant over time. If instead symptomatic individuals are most infectious immediately after symptom onset (He et al., 2020), an estimate of their contribution to transmission would in principle increase. Given the likely heightened awareness of symptoms on board however, such an increase is likely to be marginal. Indeed, since our assumption of an average one-day, exponentially distributed delay between symptom onset and removal from the ship is likely to be an overestimate, a prompter removal distribution would at least in part offset such an increase.”</p><disp-quote content-type="editor-comment"><p>3) How well supported by data is the 1 day mean (and exponential distribution, which is probably wrong) of time to removal post-test+? Does changing this to an immediate end to infectiousness (presumably people are very careful around known positives) change things?</p></disp-quote><p>We have addressed this point together with point 2 in a paragraph added to the Discussion, under ‘Limitations’. See point 2 above for details.</p><disp-quote content-type="editor-comment"><p>4) The conclusions are critically conditional on the setting. This needs to be emphasized in a whole paragraph of the Discussion, including how they might change in a setting of less intense testing and removal. For example if symptomatic test+ people are removed very fast (on average) this will increase the proportion of transmission by asymptomatics, at least in a period where only symptomatics are tested. So it is important to avoid the situation where this high proportion of contribution to transmission becomes interpreted as a constant of nature rather than a property of transmission on the DP.</p></disp-quote><p>We agree that this is an important point. We have added a paragraph to the Discussion under ‘Interpretation’ to highlight this:</p><p>“It is important to note that our conclusion that asymptomatic infections may have contributed substantially to ongoing transmission is critically dependent on the setting. In this case symptomatic infections were quickly identified and removed from the ship before symptom-agnostic testing began, thereby leaving asymptomatic infections to dominate transmission. Such dominance should therefore not be interpreted as a constant of nature, but instead an important consideration in settings where prompt isolation of symptomatic infections is already in place but with little to no consideration for asymptomatic infections.”</p><disp-quote content-type="editor-comment"><p>5) I would like to see more explanation of why it is possible to id the % asymptomatic, and their contribution to transmission, but not a quantity that is related to the ratio of these: their relative infectiousness.</p></disp-quote><p>We have added additional details to the Results section to help provide more intuition for our results. See point 1 above for details.</p><disp-quote content-type="editor-comment"><p>6) It appears that asymptomatic infections occur independently (i.e., an individual infected by someone who is asymptomatic is no more or less likely to be asymptomatic themselves). Is this correct? If so, it is worth mentioning the assumption and possible consequences of it in the Materials and methods and Discussion. This could be an additional sensitivity analysis as well.</p></disp-quote><p>The reviewer is correct. We have added a sentence to the Materials and methods section under ‘Model’ to clarify this assumption:</p><p>“This proportion equates to a universal probability of becoming either presymptomatic or asymptomatic, independent of who infected whom.”</p><p>We have also added a paragraph to the Discussion under ‘Limitations’ to highlight this assumption:</p><p>“A similar simplification was made by assuming that the probability of an individual progressing to either a presymptomatic or asymptomatic infection was independent of who infected whom. It is possible, however, that transmission from a symptomatic infection may be more likely to ultimately result in another symptomatic infection, owing to a higher infecting dose for example.”</p><disp-quote content-type="editor-comment"><p>7) It would be helpful to explain the assumptions about the testing regime in the main text. Sensitivity analyses should also consider if the testing is not truly random sampling of non-symptomatic individuals. E.g., what if individuals with infection are more likely to get tested (low-level symptoms they do not report)? Or what if individuals with infection are less likely to get tested (health-seeking behavior)? Since it relates directly to the number of asymptomatic infections in the model, it might have a larger effect than some of the other sensitivity tests.</p></disp-quote><p>We agree with the reviewer that this is an important consideration. Firstly, we have added a paragraph to the Materials and methods section under ‘Model’ making clearer our assumptions regarding testing:</p><p>“Symptom-agnostic testing was assumed to have been random amongst those not reporting symptoms and no delay was introduced between testing and removal of those that tested positive from the ship. […] All testing was assumed to have 100% sensitivity and specificity.”</p><p>Secondly, we have added sensitivity analyses considering biased symptom-agnostic testing. The scenarios have been added the Materials and methods section under ‘Sensitivity analyses’:</p><p>“Thirdly, we considered the impact of biased symptom-agnostic testing. Specifically, we first assumed that those that would test positive were 50% more likely to be tested, before then assuming that those that would test negative were 50% more likely to be tested, both compared to purely random testing as per the primary analysis.”</p><p>The results of these analyses are presented in Appendix 2—figures 12-19. A new paragraph summarising these results has also been added to the Results section, under ‘Sensitivity analyses’:</p><p>“Biased symptom-agnostic testing had a greater impact on the results. […] Conversely, those testing positive having a 50% higher probability of being tested compared to the primary analysis led to a corresponding smaller proportion of infections that were asymptomatic (66%, 61-71%), total number infected (1,051, 965-1,161) and contribution of asymptomatics to transmission (59%, 9-79%) (see Appendix 2—figures 16-19).”</p><p>Finally, we have added some discussion of biased symptom-agnostic testing to the Discussion, under ‘Limitations’:</p><p>“Whilst symptom-agnostic testing provided valuable insights into the pre- and asymptomatic states, such testing was not necessarily random, as was assumed in our primary analysis. Indeed, it is known that individuals were generally screened in reverse age order (Field Briefing: Diamond Princess COVID-19 Cases, 2020). Sensitivity analyses considering biased testing still produced non-trivial results for the proportion of infections that were asymptomatic however.”</p><disp-quote content-type="editor-comment"><p>8) If possible, it would be good to see the percentage of infections that are by pre and asymptomatic individuals by date, to see how it changes with the progression of the epidemic and the progression to symptoms within individuals.</p></disp-quote><p>Figure 3 has been added, showing these results. A reference to Figure 3 has been added to the Results section under ‘Asymptomatic infections’:</p><p>“Figure 3 shows the instantaneous proportion of transmission from symptomatic (A), presymptomatic (B) and asymptomatic (C) individuals over the course of the epidemic.”</p><p>Description of how the contents of Figure 3 were calculated has been added to Appendix 1, under ‘Model outputs’:</p><p>“The instantaneous proportion of transmission from either symptomatic, presymptomatic or asymptomatic individuals was calculated by dividing the number of infections generated by the respective infected state in the previous timestep by the total number of new infections in the previous timestep.”</p></body></sub-article></article>